Real‐world data on pain management and effectiveness of anti‐tumor necrosis factor agents in refractory livedoid vasculopathy

2021 ◽  
Author(s):  
Yimeng Gao ◽  
Hongzhong Jin
Keyword(s):  
Pain Management ◽  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
Real World Data ◽  
World Data ◽  
Livedoid Vasculopathy ◽  
Necrosis Factor

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States

2011 ◽  
Vol 15 (2) ◽  
pp. 264-275 ◽  
Author(s):  
Vernon F. Schabert ◽  
Crystal Watson ◽  
Shravanthi R. Gandra ◽  
Seth Goodman ◽  
Kathleen M. Fox ◽  
...  
Keyword(s):  
United States ◽  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
The United States ◽  
Tumor Necrosis Factor Inhibitors ◽  
Real World Data ◽  
World Data ◽  
Necrosis Factor

scholarly journals Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

2021 ◽  
Author(s):  
David L Kaplan ◽  
Brian L Ung ◽  
Corey Pelletier ◽  
Chuka Udeze ◽  
Ibrahim Khilfeh ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
Claims Data ◽  
Tumor Necrosis Factor Inhibitor ◽  
Total Cost ◽  
Factor Inhibitor ◽  
Treatment Data ◽  
Necrosis Factor

Aim: Real-world treatment data for psoriatic arthritis are limited. We evaluated switch rates, adherence, and costs for patients initiating apremilast versus tumor necrosis factor inhibitor (TNFi) and interleukin inhibitor (ILi) among biologic-naive psoriatic arthritis patients. Materials & methods: This retrospective analysis used IBM MarketScan claims data to assess treatment switches, adherence and costs. Results: Twelve-month switch rates were significantly lower for apremilast versus TNFi (15.5% vs 26.6%; p < 0.0001) and similar to ILi (15.5% vs 14.0%; p = 0.71). Apremilast initiators had lower total costs versus TNFi and ILi (US$39,854 vs US$57,243 and US$65,687; p < 0.05) and adherence was slightly lower versus TNFi and higher versus ILi. Conclusion: Biologic-naive apremilast initiators had lower switch rates versus TNFi initiators and lower total costs versus TNFi or ILi initiators.

Sign in / Sign up

Export Citation Format

Share Document